Vera Therapeutics (VERA) Common Equity (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Common Equity data on file, last reported at $499.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 6.6% year-over-year to $499.7 million; the trailing twelve-month figure through Mar 2026 stood at $499.7 million (down 6.6% YoY), and the FY2025 full-year result was $604.5 million, up 4.74% from the prior year.
• Common Equity for Q1 2026 stood at $499.7 million, down from $604.5 million in the prior quarter.
• Across five years, Common Equity topped out at $604.5 million in Q4 2025 and bottomed at $76.9 million in Q4 2022.
• The 5-year median for Common Equity is $289.1 million (2024), against an average of $295.1 million.
• The widest annual swing landed in 2024, when Common Equity soared 467.59%; it then dropped 6.6% in 2026.
• A 5-year view of Common Equity shows it stood at $76.9 million in 2022, then jumped by 32.22% to $101.7 million in 2023, then jumped by 467.59% to $577.2 million in 2024, then increased by 4.74% to $604.5 million in 2025, then slipped by 17.34% to $499.7 million in 2026.
• The last three Common Equity figures came in at $499.7 million (Q1 2026), $604.5 million (Q4 2025), and $398.9 million (Q3 2025), per Business Quant data.

Peer Comparison